Cell Cycle/Checkpoint

12R-LOX-IN-2 is a 12R-LOX inhibitor that inhibits the hyperproliferation of psoriatic cells and can be used in the study of psoriasis and other skin diseases.

Fibronectin CS1 peptide inhibits tumor metastasis, lacking RGD domain; may aid cancer therapy.

CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.

5’-O-TBDMS-dG is a modified nucleoside. 5’-O-DMT-2’-O-TBDMS-rI can be used in the synthesis of deoxyribonucleic acid or nucleic acid.

CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.

KIF2C-IN-1 (Compound 7S9) is a selective and potent small molecule inhibitor of KIF2C. It stabilizes the interaction between KIF2C and microtubule proteins, preventing the depolymerization of polyglutamylated microtubules. KIF2C-IN-1 enhances the cytotoxicity of Paclitaxel in Paclitaxel-resistant triple-negative breast cancer (TNBC) cells and, when combined with Paclitaxel, significantly reduces tumor growth in mouse models.

Chrexanthomycin C, orally active, binds DNA (G4C2)4 G4, Kd 2.8 mM, potential in ALS research.

N6-Methyl-2’-O-(2-methoxyethyl) adenosine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid malignancies.

Pyrindamycin A is an antibiotic that inhibits DNA synthesis,and shows antitumor activities against murine leukemia.

Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.

PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (

BAY-728 serves as a negative control for BAY-805, a potent and selective inhibitor of USP21 [1].

MYC-IN-2 is a protein-protein inhibitor targeting the MYC protein, designed for use in cancer research.

CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.

PAT-LM1 is a human monoclonal antibody that targets NRB54/NONO. It is applicable in the study of hematological malignancies.

DSPE-PEG1000-iRGD is a PEG compound made from DSPE and the αv-integrin-targeting peptide (iRGD). The iRGD peptide initially binds to αv-integrins and undergoes proteolytic cleavage within tumors to produce CRGDK/R, which interacts with neuropilin-1, thereby facilitating tumor targeting and penetration. DSPE-PEG1000-iRGD is useful for drug delivery applications.

BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.

Fluorocitabine HCl, a cytarabine analog, hydrolyzes into ara-FC and ara-FU, showing antitumor effects in leukemia and solid cancers.

MRK-952 is a NUDIX hydrolase inhibitor. NUDIX enzymes play a role in cellular metabolism, homeostasis, and mRNA processing.

THK01: ROCK2 inhibitor (IC50=5.7nM), less effective on ROCK1 (923nM). Hinders breast cancer spread via ROCK2-STAT3. For cancer research.

DHFR-IN-8 (compound 6r), a dihydrofolate reductase (DHFR) inhibitor, disrupts purine and thymidylate biosynthesis critical for cell proliferation and growth.

3’-β-C-Methyl-2-thiouridine, a purine nucleoside analog, exhibits extensive antitumor activity, particularly against indolent lymphoid malignancies.

CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.

DSPE-PEG5000-cRGD is a PEG compound composed of DSPE and an αvβ3 targeting peptide (cRGD). The cRGD peptide has the ability to specifically bind to the αvβ3 present on the surfaces of numerous cancer cells and new vascular cells. DSPE-PEG5000-cRGD is useful for drug delivery applications.

Anti-EMMPRIN/CD147 Antibody is a human-derived antibody expressed in CHO cells, targeting Basigin. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) is used as a soluble integrin-blocking RGD-based peptide.

dAURK-4, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].

K34c hydrochloride is an alpha5β1 integrin antagonist for glioblastoma study.

HDAC-IN-85 (Compound 1) is an HDAC inhibitor capable of crossing the blood-brain barrier. It exhibits inhibitory effects on brain tumor cell lines and can induce acetylation, resulting in DNA double-strand breaks and promoting RAD51 ubiquitination, which disrupts the DNA repair process. HDAC-IN-85 is applicable in studies of glioblastoma.

Compound PDK0016, with CAS No. 108-53-2, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0016 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound 19c is a nucleotide derivative for DNA sequencing dye terminators.

ROCK-IN-5 (I-B-37) inhibits kinases like ROCK/ERK/GSK; may aid in cardiac and neuro disease studies.

N1-Methylpseudouridine-5′-triphosphate tetralithium, also known as 1-Methylpseudouridine-5′-triphosphate tetralithium, is a nucleobase-modified nucleotide.

N3,5-Dimethyl-2’-O-(2-methoxyethyl) uridine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid malignancies.

Stigmatellin is an antibiotic derived from the cell mass of the myxobacterium, effective against yeasts (yeasts), filamentous fungi (filamentous fungi), and several Gram-positive bacteria (Gram-positive bacteria). Additionally, it serves as a potent inhibitor of photosynthetic electron (photosynthetic electron) transfer. Stigmatellin utilizes various sugars, polysaccharides, and acids from the citric acid cycle as substrates, inhibiting RNA and protein synthesis. It has two different inhibitory sites: one located on the reducing side of photosystem II and the other at the cytochrome b6/f complex. Stigmatellin holds potential for use in antimicrobial and photosynthesis research.

DSPE-PEG2000-cRGD is a PEG compound composed of DSPE and an αvβ3-targeting peptide (cRGD). The cRGD peptide specifically binds to αvβ3 on the surface of various cancer cells and neovascular cells. This compound can be utilized for drug delivery.

2’-Chloro-N6-(3-trifluoromethyl)benzyl adenosine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid

α4β1 integrin (VLA-4) ligand (Kd ~ 12 nM). Non-fluorescent derivative of LDV FITC.

Biotin-PEG7-C2-NH-Vidarabine-S-CH3 is a PEG linker with Vidarabine, an anti-herpes/zoster antiviral.

Remdesivir metabolite, antiviral nucleoside analog, effective against SARS-CoV and MERS-CoV.

N1-Methylxylo-guanosine, a purine analog, targets lymphoid cancer via DNA synthesis inhibition and apoptosis.

Pseudouridimycin: a C-nucleoside antibiotic, inhibits bacterial RNAP, targets Gram-negative and Gram-positive bacteria.

Esperamicin A1, a powerful antitumor drug, comes from Actinomadura verrucosospora.

PKMYT1-IN-3 (compound 8ma) is a potent, selective inhibitor of PKMYT1, demonstrating an IC50 of 16.5 nM and exhibiting antitumor activity.

2'-Deoxy-2'-fluoro-1-uridine: an L-nucleoside, inhibits RNA viruses by blocking viral RNA polymerase.

DSPE-PEG2000-iRGD is a PEG compound composed of DSPE and the αv-integrin targeting peptide (iRGD). The iRGD peptide binds to αv-integrins and subsequently undergoes proteolytic cleavage within tumors, producing CRGDK/R, which interacts with neuropilin-1. This compound is characterized by its tumor-targeting and tumor-penetrating properties, making DSPE-PEG2000-iRGD suitable for drug delivery applications.

Phen-DC3 Trifluoromethanesulfonate targets G-quadruplexes and inhibits FANCJ/DinG helicases; IC50s: 65±6/50±10 nM.

Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.

SP27, a selective PROTAC, degrades PLK4 with a DC50 of 19.5 nM and may be utilized in breast cancer research [1].